Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A phase 1 trial called ASCEND is testing INS1201, a novel AAV9 gene therapy for Duchenne muscular dystrophy (DMD) delivered directly into the spinal fluid rather than through an IV. The study enrolls up to 12 young ambulatory boys and aims to assess safety and dosing. This approach may help avoid the liver toxicity concerns that recently led to safety warnings for Elevidys, the only currently approved DMD gene therapy.
A new gene therapy approach for Duchenne muscular dystrophy (DMD) is entering human trials — and it's taking a notably different path to the body. Insmed's INS1201 is an AAV9-based micro-dystrophin therapy delivered via a single intrathecal injection into the cerebrospinal fluid (CSF), rather than the intravenous route used by Elevidys, the only currently FDA-approved DMD gene therapy. The phase 1 ASCEND trial is enrolling up to 12 ambulatory boys ages 2–5 with genetically confirmed DMD across 10 U.S. sites.
The intrathecal delivery strategy isn't just a technical tweak — it's a potential safety advantage. Preclinical data showed that CSF-delivered INS1201 reached muscles throughout the body, including the heart, while limiting liver exposure. That matters because Elevidys received a boxed warning in November 2025 after two non-ambulatory boys died from acute liver failure following IV infusion.
By the Numbers:
Why it matters: With Elevidys's safety profile under scrutiny, INS1201's CSF-based delivery could offer a safer path to getting micro-dystrophin into muscles — potentially reshaping how DMD gene therapy is administered.
